Difference between revisions of "Stanisław Burzyński"
(tp) |
|||
| Line 1: | Line 1: | ||
[[image:burzynski.jpg|Stanisław Burzyński|right]] | [[image:burzynski.jpg|Stanisław Burzyński|right]] | ||
| − | '''Stanislaw Rajmund Burzynski''' (born January 23, 1943 in Lublin, Poland) is a biochemist and a physician. He is founder, | + | '''Stanislaw Rajmund Burzynski''' (born January 23, 1943 in Lublin, Poland) is a biochemist and a physician. He is the founder, president and chairman of '''Burzynski Research Institute Inc.''' , based in Houston and Stafford, Texas. Since December 1976, Burzynski administered peptides and their metabolites, which he calls ''[[antineoplaston]]s'', as a treatment against cancer. |
== Legal issues == | == Legal issues == | ||
| − | In 1993, Burzynski was brought to court in Texas for treating patients with a | + | In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.<ref name=opinion>[http://www.3rdcoa.courts.state.tx.us/opinions/HTMLopinion.asp?OpinionID=847 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee] Court judgement</ref><ref name="openjurist1987"/> In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons<ref>{{cite web | author = Texas Attorney General's Office | title = Limits Placed on Burzynski's Cancer Treatment | url = http://www.quackwatch.org/04ConsumerEducation/News/burzynski.html | date = 1998-02-10 | accessdate = 2007-05-10|format=courtesy copy}}</ref> and ordered him to cease and desist selling his products without FDA supervised clinical trials.<ref name=1994judgement/> Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."<ref name=opinion/> Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a [[health insurer]] for a cancer treatment administered illegally.<ref name=1994judgement>[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf No. 93-2071] July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.</ref> |
| − | Burzynski | + | Burzynski will have a hearing with the Texas Medical Board in April 2012. The board might well revoke his approbation. |
Main Article: | Main Article: | ||
Revision as of 15:35, 30 November 2011
Stanislaw Rajmund Burzynski (born January 23, 1943 in Lublin, Poland) is a biochemist and a physician. He is the founder, president and chairman of Burzynski Research Institute Inc. , based in Houston and Stafford, Texas. Since December 1976, Burzynski administered peptides and their metabolites, which he calls antineoplastons, as a treatment against cancer.
Legal issues
In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.[1][2] In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons[3] and ordered him to cease and desist selling his products without FDA supervised clinical trials.[4] Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."[1] Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a health insurer for a cancer treatment administered illegally.[4] Burzynski will have a hearing with the Texas Medical Board in April 2012. The board might well revoke his approbation.
Main Article: Antineoplaston
Links
- ↑ 1.0 1.1 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee Court judgement
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedopenjurist1987 - ↑ Template:Cite web
- ↑ 4.0 4.1 No. 93-2071 July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.